Browsing Tag
Prostate cancer
33 posts
How next-generation masking strategies could reshape PSMA-directed T cell engager development
How Janux Therapeutics is advancing masked T cell engagers with JANX014. Find out what this means for prostate cancer treatment and immunotherapy.
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
Johnson & Johnson’s AKEEGA clears major EU hurdle with CHMP nod for mHSPC BRCA mutation indication
Johnson & Johnson’s EU backing for AKEEGA’s expanded prostate cancer label could reshape its oncology strategy and precision medicine footprint in 2026.
Halda Therapeutics joins Johnson & Johnson in $3bn cancer drug platform deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B. Find out why its RIPTAC platform could reshape prostate and solid tumor cancer treatment.
Rubraca beats docetaxel in TRITON3: FDA clears early-line prostate cancer use for Tolmar
Tolmar’s Rubraca gains FDA approval for BRCA-mutated prostate cancer before chemotherapy. Explore the trial results and what it means for treatment strategy.
Alpha Tau advances alpha DaRT with FDA approval for recurrent prostate cancer study
Find out how Alpha Tau’s FDA-approved prostate cancer trial could redefine localized salvage therapy and reshape treatment for recurrent disease.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
EDX Medical (AQSE: EDX) secures £4m to scale oncology diagnostics and fast-track commercial rollout
EDX Medical secures £4 million to fund oncology diagnostics and market rollout. See how founder Chris Evans and institutional investors are backing its next phase.
Telix Pharmaceuticals (ASX: TLX) jumps 16% after CMS greenlight and Illuccix’s European rollout
Telix Pharmaceuticals raises FY25 revenue guidance after securing CMS reimbursement for Gozellix and accelerating Illuccix's launch in Europe. Learn what’s next.
MiraDx’s ASTRO 2025 breakthrough: Can PROSTOX ultra finally make radiation therapy safer for prostate cancer patients?
MiraDx’s PROSTOX ultra test at ASTRO 2025 shows high-risk prostate cancer patients can avoid SBRT toxicity with safer regimens. Read the full story.